Fig. 6.

Protective effects of SPAK inhibitor ZT-1a at 4–8 weeks post-BCAS. A Experimental protocol. C57BL/6 J mice underwent sham, BCAS + Veh (100% DMSO, 2 ml/kg body weight/ day, i.p.), or BCAS + ZT-1a (5 mg/kg/day, via intraperitoneal injection, i.p.) at 28-56d. Arrowheads: indicate the time points at which drug treatment, CBF or behavioral test were performed B Representative periCam PSI images of rCBF at 56 days (8-weeks) after surgery. Dashed circle: region of interest (ROI). C Quantification analysis of rCBF. Data are expressed as mean ± SD. n = 4 mice. *p < 0.05, ***p < 0.001 vs. Sham. One-way analysis of variance (ANOVA). D The percentage of spontaneous alternation and total entry in Y maze test. n = 10–12 mice. *p < 0.05, **p < 0.01. One-way analysis of variance (ANOVA). E The recognition index of the Novel Spatial Recognition (NSR) test. Data are represented as mean ± SD. n = 8–10 mice. *p < 0.05, ** < 0.01 vs. sham. One-way analysis of variance (ANOVA)